Poly Medicure Limited — Updates, 03-02-2025: Press Release

Poly Medicure Limited reported strong consolidated financial results for the third quarter and nine months ended December 31, 2024, with a 25% and 23% year-on-year increase in revenue, respectively. The consolidated EBITDA surged by 28% in Q3, achieving a core EBITDA margin of 27.4%, while profit after tax (PAT) grew by 31%, with a PAT margin of 20.1%. Export revenues rose 29%, bolstered by robust international market performance, and domestic growth stood at 24% for the quarter. Notably, the renal division showed impressive growth, with a 50% revenue increase in Q3.

The company’s balance sheet remains strong, featuring a net cash position of Rs. 1,074 cr. Management expressed confidence in achieving a revenue growth rate of 22% to 24% and enhancing EBITDA margins further. The recent regulatory approval for a new Drug Eluting Stent and the establishment of a significant solar power joint venture underline Poly Medicure's commitment to sustainability and growth in India's MedTech sector. Investors should watch this trajectory closely, as these developments may signal substantial future opportunities.